A Non-interventional Observational Post Authorization Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands (OCEAN)
Latest Information Update: 25 Jul 2019
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Breast cancer; Chronic myelomonocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Graft-versus-host disease; Leukaemia; Myelodysplastic syndromes; Nasopharyngeal cancer; Non-small cell lung cancer; Peripheral T-cell lymphoma; Renal cancer; Solid tumours
- Focus Adverse reactions
- Acronyms OCEAN
- Sponsors Celgene Corporation
- 23 Jul 2019 Status changed from active, no longer recruiting to completed.
- 25 Oct 2018 Status changed to active, no longer recruiting.
- 23 Sep 2016 New trial record